Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Ginkgo Bioworks Holdings (DNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: DNA (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.33
1 Year Target Price $11.33
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 3 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 11.77% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 592.59M USD | Price to earnings Ratio - | 1Y Target Price 11.33 |
Price to earnings Ratio - | 1Y Target Price 11.33 | ||
Volume (30-day avg) 6 | Beta 1.51 | 52 Weeks Range 5.00 - 16.85 | Updated Date 09/14/2025 |
52 Weeks Range 5.00 - 16.85 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -136.56% | Operating Margin (TTM) -124.72% |
Management Effectiveness
Return on Assets (TTM) -12.9% | Return on Equity (TTM) -43.6% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 547725526 | Price to Sales(TTM) 2.57 |
Enterprise Value 547725526 | Price to Sales(TTM) 2.57 | ||
Enterprise Value to Revenue 2.37 | Enterprise Value to EBITDA -1.79 | Shares Outstanding 47089600 | Shares Floating 37806175 |
Shares Outstanding 47089600 | Shares Floating 37806175 | ||
Percent Insiders 6.73 | Percent Institutions 79.11 |
Upturn AI SWOT
Ginkgo Bioworks Holdings
Company Overview
History and Background
Ginkgo Bioworks was founded in 2008 by MIT graduates. It focuses on using genetic engineering to design and create biological products. Significant milestones include strategic partnerships and expansion into various industries.
Core Business Areas
- Foundry: Ginkgo's core service; it provides a platform for designing and prototyping engineered organisms.
- Biosecurity: Offers services related to pathogen monitoring and identification through Concentric, Ginkgo's biosecurity and public health initiative.
Leadership and Structure
Jason Kelly is the CEO and co-founder. The company has a structured management team and a board of directors overseeing its operations.
Top Products and Market Share
Key Offerings
- Cell Programming Platform: Ginkgou2019s cell programming platform is a comprehensive suite of services for designing, building, and testing engineered organisms. Ginkgo focuses on serving companies that want to develop new products by engineering biology and don't have a ton of internal bioengineering capabilities. Competitors include Amyris (AMRS).
- Concentric by Ginkgo: Concentric by Ginkgo is Ginkgo's biosecurity initiative, which focuses on developing and deploying solutions for pathogen monitoring and detection. Public sector clients are primary customers. Competitors include Thermo Fisher Scientific (TMO) and Illumina (ILMN).
Market Dynamics
Industry Overview
The synthetic biology industry is growing, driven by advancements in genetic engineering, increasing demand for sustainable products, and rising investments in R&D.
Positioning
Ginkgo Bioworks is a leading player in the synthetic biology industry, differentiating itself through its cell programming platform and partnerships.
Total Addressable Market (TAM)
The synthetic biology market is estimated to be in the tens of billions of dollars. Ginkgo is positioned to capture a significant portion of this market with its foundry platform.
Upturn SWOT Analysis
Strengths
- Proprietary cell programming platform
- Strategic partnerships
- Strong R&D capabilities
- First mover advantage in a growing market
Weaknesses
- High operating expenses
- Reliance on partnerships
- Long development cycles
- Cash Burn Rate
Opportunities
- Expanding into new markets (e.g., agriculture, pharmaceuticals)
- Developing new applications for its platform
- Acquiring complementary technologies
- Government funding for biosecurity initiatives
Threats
- Competition from established players
- Regulatory hurdles
- Technological advancements by competitors
- Economic downturn affecting R&D spending
Competitors and Market Share
Key Competitors
- AMRS
- DNA
Competitive Landscape
Ginkgo has an advantage in its foundry and strategic partnerships but faces competition on pricing, technology, and customer relationships.
Major Acquisitions
Zymergen
- Year: 2022
- Acquisition Price (USD millions): 300
- Strategic Rationale: Expanded Ginkgo's codebase, added key personnel, and secured critical infrastructure to boost Ginkgo's capabilities and scale
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by expanding partnerships and technological advancements.
Future Projections: Future growth projections depend on the continued adoption of synthetic biology and Ginkgo's ability to execute its strategy. Analyst estimates vary. Refer to latest research reports.
Recent Initiatives: Recent initiatives include strategic acquisitions and expansion into new markets.
Summary
Ginkgo Bioworks is a prominent player in synthetic biology with a robust cell programming platform, yet faces significant financial challenges. The company's strength lies in its partnerships and technological innovation, while weaknesses include high operating expenses and reliance on external collaborations. Growth prospects are promising, but it must carefully manage competition, regulatory hurdles, and economic uncertainties to realize its full potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Press releases
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ginkgo Bioworks Holdings
Exchange NYSE | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-04-19 | Founder, CEO & Director Dr. Jason Kelly Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 834 | Website https://www.ginkgo.bio |
Full time employees 834 | Website https://www.ginkgo.bio | ||
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.